Your email has been successfully added to our mailing list.

×
0.00375234521575994 0.000234521575984944 -0.00211069418386483 -0.0100844277673546 0.0727016885553471 0.0900562851782365 0.0954502814258912 0.0689493433395874
Stock impact report

Septerna, in market debut, surges at open [Seeking Alpha]

Septerna, Inc. (SEPN) 
Company Research Source: Seeking Alpha
The pharma's lead candidate is SEP-786, a PTH1R agonist in phase 1 for hypoparathyroidism. In a prior SEC filing, Septerna said it planned to offer ~11M shares at $15-$17 a share. At that price, the company expected an IPO of $175M. More on Septerna Septerna Pursues $100 Million IPO For Endocrine And Metabolic Drug Pipeline Septerna proposes terms for upsized $175M IPO IPO Roundup: KinderCare Learnings, Moove and more Financial information for Septerna, Inc. Recommended For You More Trending News Show less Read more
Impact Snapshot
Event Time:
SEPN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for
SEPN alerts

from News Quantified
Opt-in for
SEPN alerts

from News Quantified